• 

  3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. 

  Iveson, TJ; Kerr, RS; Saunders, MP; Cassidy, J; Hollander, NH; Tabernero, J; Haydon, A; Glimelius, B; Harkin, A; Allan, K; McQueen, J; Scudder, C; Boyd, KA; Briggs, A; Waterston, A; Medley, L; Wilson, C; Ellis, R; Essapen, S; Dhadda, AS; Harrison, M; Falk, S; Raouf, S; Rees, C; Olesen, RK; Propper, D; Bridgewater, J; Azzabi, A; Farrugia, D; Webb, A; Cunningham, D; Hickish, T; Weaver, A; Gollins, S; Wasan, HS; Paul, J (2018-04)

  BACKGROUND: 6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether 3 months of oxaliplatin-containing chemotherapy would be non-inferior ...
• 

  Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. 

  Sydes, MR; Spears, MR; Mason, MD; Clarke, NW; Dearnaley, DP; de Bono, JS; Attard, G; Chowdhury, S; Cross, B; Gillessen, S; Malik, Z; Jones, R; Parker, C; Ritchie, AWS; Russell, JM; Millman, R; Matheson, D; Amos, C; Gilson, C; Birtle, A; Brock, S; Capaldi, L; Chakraborti, P; Choudhury, A; Evans, L; Ford, D; Gale, J; Gibbs, S; Gilbert, D; Hughes, R; McLaren, D; Lester, J; Nikapota, A; O'Sullivan, J; Parikh, O; Peedell, C; Protheroe, A; Rudman, SM; Shaffer, R; Sheehan, D; Simms, M; Srihari, N; Strebel, R; Sundar, S; Tolan, S; Tsang, D; Varughese, M; Wagstaff, J; Parmar, MKB; James, ND (2018-02-26)

  Background: Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in STAMPEDE: a multi-arm multi-stage platform randomised controlled ...
• 

  Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). 

  Mehra, N; Dolling, D; Sumanasuriya, S; Christova, R; Pope, L; Carreira, S; Seed, G; Yuan, W; Goodall, J; Hall, E; Flohr, P; Boysen, G; Bianchini, D; Sartor, O; Eisenberger, MA; Fizazi, K; Oudard, S; Chadjaa, M; Macé, S; de Bono, JS (2018-02-28)

  BACKGROUND: Noninvasive biomarkers are needed to guide metastatic castration-resistant prostate cancer (mCRPC) treatment. OBJECTIVE: To clinically qualify baseline and on-treatment cell-free DNA (cfDNA) concentrations as ...
• 

  Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study. 

  Hewitt, LC; Inam, IZ; Saito, Y; Yoshikawa, T; Quaas, A; Hoelscher, A; Bollschweiler, E; Fazzi, GE; Melotte, V; Langley, RE; Nankivell, M; Cunningham, D; Allum, W; Hutchins, GG; Grabsch, HI (2018-05)

  BACKGROUND: Oesophageal (OeC) and gastric (GC) cancer patients are treated with similar multimodal therapy and have poor survival. There remains an urgent clinical need to identify biomarkers to individualise patient ...
• 

  Outcome of elderly advanced soft tissue sarcoma patients treated with first line chemotherapy: a pooled analysis of twelve EORTC Soft Tissue and Bone sarcoma Group Trials 

  van der Graaf, W; Jones, R
• 

  Ki67 Is an Independent Predictor of Recurrence in the Largest Randomized Trial of 3 Radiation Fractionation Schedules in Localized Prostate Cancer. 

  Wilkins, AC; Gusterson, B; Szijgyarto, Z; Haviland, J; Griffin, C; Stuttle, C; Daley, F; Corbishley, CM; Dearnaley, DP; Hall, E; Somaiah, N; CHHiP Trial Investigators (2018-02-03)

  PURPOSE: To assess whether the cellular proliferation marker Ki67 provides prognostic information and predicts response to radiation therapy fractionation in patients with localized prostate tumors participating in a ...
• 

  Health-related quality of life in sarcoma patients: enhancing personalized medicine. 

  van der Graaf, W
• 

  Proton Beam Therapy - the Challenges of Delivering High-quality Evidence of Clinical Benefit 

  Amos, R; Bulbeck, H; Burnet, NG; Crellin, A; Eaton, D; Evans, P; Hall, E; Hawkins, MA; Kirkby, KJ; Mackay, R; Sebag-Montefiore, D; Sharma, R; Inst, NCR; Translational, C; Trial, PBC (2018-05)
• 

  The role of genomic profiling in adolescents and young adults (AYAs) with advanced cancer participating in phase I clinical trials. 

  McVeigh, TP; Sundar, R; Diamantis, N; Kaye, SB; Banerji, U; Lopez, JS; de Bono, J; van der Graaf, WTA; George, AJ (2018-03-31)

  INTRODUCTION: Adolescents and young adults (AYAs) diagnosed with cancer between ages 15-39 years may harbour germline variants associated with cancer predisposition. Such variants represent putative therapeutic targets, ...
• 

  A randomised phase III trial of carboplatin compared with docetaxel in BRCA1/2 mutated and 2 pre-specified triple negative breast cancer “BRCAness” subgroups: the TNT Trial 3 4 

  Tutt, A; Tovey, H; Cheang, M; Kernaghan, S; Kilburn, L; Gazinska, P; Owen, J; Abraham, J; Barrett, S; Barrett-Lee, P; Brown, R; Chan, S; Dowsett, M; Flanagan, J; Fox, L; Grigoriadis, A; Gutin, A; Harper-Wynne, C; Hatton, M; Hoadley, K; Parikh, J; Parker, P; Perou, C; Roylance, R; Shah, V; Shaw, A; Smith, I; Timms, K; Wardley, A; Wilson, G; Gillet, C; Lanchbury, J; Ashworth, A; Rahman, N; Harries, M; Ellis, P; Pinder, S; Bliss, J
• 

  Patient Involvement in the Design of a Phase III Trial Comparing Intensity-modulated Proton Therapy and Intensity-modulated Radiotherapy for Oropharyngeal Cancer. 

  Hague, C; Foran, B; Hall, E; Guild, S; Joseph, O; Moule, R; Nutting, C; Parsons, S; Prestwich, R; Slevin, N; West, C; Thomson, D (2018-05)
• 

  Prognostic value of pathological lymph node status and primary tumour regression grading following neoadjuvant chemotherapy - results from the MRC OE02 oesophageal cancer trial. 

  Davarzani, N; Hutchins, GGA; West, NP; Hewitt, LC; Nankivell, M; Cunningham, D; Allum, WH; Smyth, E; Valeri, N; Langley, RE; Grabsch, HI (2018-02-21)

  AIMS: Neoadjuvant chemotherapy (NAC) remains an important therapeutic option for advanced oesophageal cancer (OC). Pathological tumour regression grade (TRG) may offer additional information by directing adjuvant treatment ...
• 

  Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer. 

  von Minckwitz, G; Procter, M; de Azambuja, E; Zardavas, D; Benyunes, M; Viale, G; Suter, T; Arahmani, A; Rouchet, N; Clark, E; Knott, A; Lang, I; Levy, C; Yardley, DA; Bines, J; Gelber, RD; Piccart, M; Baselga, J; APHINITY Steering Committee and Investigators

  BACKGROUND: Pertuzumab increases the rate of pathological complete response in the preoperative context and increases overall survival among patients with metastatic disease when it is added to trastuzumab and chemotherapy ...
• 

  Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database. 

  Sleijfer, S; Rizzo, E; Litière, S; Mathijssen, RHJ; Judson, IR; Gelderblom, H; Van Der Graaf, WTA; Gronchi, A (2018-03-09)

  INTRODUCTION: As both anti-tumour effects and toxicity are thought to be dose-dependent, patients with the greatest toxicity may also have the best outcome. We assessed whether severity of doxorubicin-induced hematological ...
• 

  Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models. 

  Wong Te Fong, A-C; Thavasu, P; Gagrica, S; Swales, KE; Leach, MO; Cosulich, SC; Chung, Y-L; Banerji, U (2017-12-26)

  Activation of the PI3K/mTOR pathway has been shown to be correlated with resistance to chemotherapy in ovarian cancer. We aimed to investigate the effects of combining inhibition of mTORC1 and 2 using the mTOR kinase ...
• 

  Glycogen synthase kinase 3 controls migration of the neural crest lineage in mouse and Xenopus. 

  Gonzalez Malagon, SG; Lopez Muñoz, AM; Doro, D; Bolger, TG; Poon, E; Tucker, ER; Adel Al-Lami, H; Krause, M; Phiel, CJ; Chesler, L; Liu, KJ (2018-03-19)

  Neural crest migration is critical to its physiological function. Mechanisms controlling mammalian neural crest migration are comparatively unknown, due to difficulties accessing this cell population in vivo. Here we report ...
• 

  An exploratory analysis of women’s free-text comments on their Quality of Life in the UK Standardisation of Breast Radiotherapy (START) Trials for early breast cancer 

  Haviland, J; Moynihan, C; Hopwood, P; Bliss, J
• 

  Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. 

  Eisenberger, M; Hardy-Bessard, A-C; Kim, CS; Géczi, L; Ford, D; Mourey, L; Carles, J; Parente, P; Font, A; Kacso, G; Chadjaa, M; Zhang, W; Bernard, J; de Bono, J (2017-10-01)

  Purpose Cabazitaxel 25 mg/m2 (C25) significantly improved overall survival (OS) versus mitoxantrone ( P < .001) in postdocetaxel patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase III TROPIC ...
• 

  Activity of Eribulin in Patients With Advanced Liposarcoma Demonstrated in a Subgroup Analysis From a Randomized Phase III Study of Eribulin Versus Dacarbazine. 

  Demetri, GD; Schöffski, P; Grignani, G; Blay, J-Y; Maki, RG; Van Tine, BA; Alcindor, T; Jones, RL; D'Adamo, DR; Guo, M; Chawla, S (2017-10-20)

  Purpose A phase III study comparing eribulin with dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma showed a significant improvement in overall survival (OS) for the eribulin arm, with a manageable ...
• 

  Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. 

  Gautschi, O; Milia, J; Filleron, T; Wolf, J; Carbone, DP; Owen, D; Camidge, R; Narayanan, V; Doebele, RC; Besse, B; Remon-Masip, J; Janne, PA; Awad, MM; Peled, N; Byoung, C-C; Karp, DD; Van Den Heuvel, M; Wakelee, HA; Neal, JW; Mok, TSK; Yang, JCH; Ou, S-HI; Pall, G; Froesch, P; Zalcman, G; Gandara, DR; Riess, JW; Velcheti, V; Zeidler, K; Diebold, J; Früh, M; Michels, S; Monnet, I; Popat, S; Rosell, R; Karachaliou, N; Rothschild, SI; Shih, J-Y; Warth, A; Muley, T; Cabillic, F; Mazières, J; Drilon, A (2017-05-01)

  Purpose In addition to prospective trials for non-small-cell lung cancers (NSCLCs) that are driven by less common genomic alterations, registries provide complementary information on patient response to targeted therapies. ...

View more